Glioblastoma

Score 3.9 = 3 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph3NCT06448286 · Jonsson Comprehensive Cancer Center · PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma
• Ph1NCT07218367 · VA Office of Research and Development · Phase I Trial of pH Resections of GBM at VA

Score 3.7 = 3.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph1/Ph2NCT06622434 · Assistance Publique - Hôpitaux de Paris · New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study
• Ph2NCT07347210 · Centre Hospitalier Universitaire de Besancon · Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma

Score 3.3 = 3.2 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 2 of 5 trials are Phase 2+.

• Ph1NCT03535350 · Case Comprehensive Cancer Center · Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
• Ph2NCT05607407 · Case Comprehensive Cancer Center · Methimazole in Patients With Progressive Glioblastoma
• Ph2NCT07003542 · Case Comprehensive Cancer Center · A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
• Ph1NCT03514069 · Case Comprehensive Cancer Center · Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
• Ph1NCT02669173 · Case Comprehensive Cancer Center · Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma

Score 3.3 = 3 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph1/Ph2NCT07859059 · University of Nebraska · Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma
• Ph1NCT05698524 · University of Nebraska · A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

Score 3.2 = 3.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT05969860 · Mayo Clinic · At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
• Ph2NCT07285044 · Mayo Clinic · The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Score 3.1 = 2.6 leading Phase 2+ trials + 0.5 other trial roles + 0 talks + 0 posters. 1 of 3 trials are Phase 2+.

• Ph1NCT04015700 · Washington University School of Medicine · Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma
• Ph1/Ph2NCT07392957 · Washington University School of Medicine · Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma
• Ph1NCT05743595 · Washington University School of Medicine · Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT06161974 · Rigel Pharmaceuticals · Study of Olutasidenib and Temozolomide in HGG
• Ph2NCT05843253 · Nationwide Children's Hospital · Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07620548 · Washington University School of Medicine · Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07389278 · Sabine Mueller, MD, PhD · Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07821112 · University of California, Irvine · Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07831187 · First Affiliated Hospital of Wenzhou Medical University · Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence

Score 2.9 = 2.8 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph2NCT07708961 · Mayo Clinic · Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
• Ph1NCT04197934 · Mayo Clinic · WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2/Ph3NCT07873996 · Beijing Tiantan Hospital · Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2/Ph3NCT07873996 · Beijing Tiantan Hospital · Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07831369 · Inova Health Care Services · VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07811297 · Advenchen Pharmaceuticals, LLC. · A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07735819 · Barbara Ann Karmanos Cancer Institute · Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07356973 · CRISM Therapeutics LTD · Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma

Score 2.7 = 1.7 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 2 of 5 trials are Phase 2+.

• Ph1NCT06389591 · University of Florida · RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
• Ph1NCT05353530 · University of Florida · IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma
• Ph2NCT06558214 · University of Florida · OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
• Ph2NCT03405792 · University of Florida · Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)
• Ph1NCT04963413 · University of Florida · RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06492486 · Tata Memorial Centre · Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07301268 · Mayo Clinic · GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07452458 · NRG Oncology · Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07416188 · National Institute of Neurological Disorders and Stroke (NINDS) · Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Score 2.6 = 2.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0.5 posters. 2 of 2 trials are Phase 2+.

• ESMO 2026 707P (poster) · Teniposide plus cisplatin or carboplatin in recurrent high-grade glioma: Pre-planned interim analysis of an ongoing multicenter, open-label, single-arm trial

• Ph2/Ph3NCT06105619 · Beijing Pearl Biotechnology Limited Liability Company · A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
• Ph2NCT07138001 · Sichuan Honghe Biotechnology Co., Ltd. · Phase 2 Clinical Trial of KH617

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2/Ph3NCT07605364 · Alliance for Clinical Trials in Oncology · Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07468136 · Mayo Clinic · Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2/Ph3NCT07605364 · Alliance for Clinical Trials in Oncology · Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07462507 · Washington University School of Medicine · Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

Score 2.2 = 1.2 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 2 of 4 trials are Phase 2+.

• Ph1NCT05533242 · University Hospital Muenster · Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment
• Ph1/Ph2NCT05590689 · Universität Münster · Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor
• Ph2NCT03897491 · photonamic GmbH & Co. KG · PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
• Ph1NCT06665724 · Universität Münster · Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)

Score 2.2 = 0.8 leading Phase 2+ trials + 1.3 other trial roles + 0 talks + 0 posters. 1 of 4 trials are Phase 2+.

• Ph1/Ph2NCT05432804 · National Cancer Institute (NCI) · Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
• Ph1NCT05139056 · City of Hope Medical Center · Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
• Ph1NCT07791264 · City of Hope Medical Center · FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma
• Ph1NCT02192359 · City of Hope Medical Center · Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

Score 2.2 = 2.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06991101 · Baptist Health South Florida · Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Score 2.2 = 2.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07347210 · Centre Hospitalier Universitaire de Besancon · Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma

Score 2.2 = 2.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07318818 · Tasly Pharmaceutical Group Co., Ltd · A Clinical Trial of P134 Cells in Recurrent Glioblastoma

Score 2.1 = 2.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph1/Ph2NCT03672721 · Université de Sherbrooke · IA Carboplatin + Radiotherapy in Relapsing GBM
• Ph2NCT06356883 · Université de Sherbrooke · Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma

Score 2.1 = 2 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph1NCT03911388 · M.D. Anderson Cancer Center · HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
• Ph2NCT04482933 · Pediatric Brain Tumor Consortium · HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

Score 2.1 = 2.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07461948 · Jonsson Comprehensive Cancer Center · Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients

Score 2 = 2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT06814496 · University of Arizona · Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Score 2 = 2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07093814 · Guangzhou Virotech Pharmaceutical Co., Ltd. · A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

Score 2 = 2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT06814496 · University of Arizona · Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Score 2 = 0.3 leading Phase 2+ trials + 1.6 other trial roles + 0 talks + 0 posters. 1 of 4 trials are Phase 2+.

• Ph1NCT07209241 · University of Pennsylvania · Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
• Ph1NCT06973096 · University of Pennsylvania · CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy
• Ph2NCT04225039 · University of Pennsylvania · Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
• Ph1NCT05168423 · University of Pennsylvania · CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM